ReCode Therapeutics

ReCode Therapeutics is a biopharmaceutical company based in Menlo Park, California, focused on developing precision medicines for pulmonary diseases. Founded in 2015, the company employs a non-viral lipid nanoparticle platform that enables targeted delivery of genetic therapies to specific organs and tissues. This innovative approach aims to address the limitations of existing gene therapy methods, particularly for patients with rare diseases such as primary ciliary dyskinesia and cystic fibrosis. By delivering corrective or disease-modifying therapies, ReCode Therapeutics seeks to provide new treatment options for individuals suffering from life-limiting respiratory conditions, thereby addressing significant unmet medical needs in the healthcare sector.